F9 and hemophilia B: The first successful gene transfers in this field were in people with hemophilia B, where single infusions of AAV expressing optimized human F9 transgenes have produced sustained therapeutic expression of factor IX coagulant activity [12–14], with longer-term follow-up demonstrating sustained activity for up to 8 years at the time of reporting [15].